Research programme: gene circuit engineered induced pluripotent stem cell therapeutics - BlueRock Therapeutics
Latest Information Update: 30 Aug 2022
At a glance
- Originator BlueRock Therapeutics
- Class Gene therapies; Induced pluripotent stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cardiovascular disorders; Immunological disorders; Neurological disorders
Most Recent Events
- 24 Aug 2022 BioCardia and BlueRock Therapeutics agree to co-develop in cell therapy product candidates for Cardiovascular disorders
- 26 May 2021 BlueRock Therapeutics and Senti Biosciences enter into a collaboration and option agreement for gene circuit engineered cell therapies
- 26 May 2021 Early research in Cardiovascular disorders in USA (Parenteral)